Showing 881 - 900 results of 30,739 for search '(( 2 step decrease ) OR ( 50 ((((mg decrease) OR (a decrease))) OR (nn decrease)) ))', query time: 0.93s Refine Results
  1. 881
  2. 882
  3. 883

    Substance P decreases PRL immunoreactivity in human epidermis. by Ewan A. Langan (405804)

    Published 2013
    “…<p>Epidermal PRL IR (black arrows) was examined in full-thickness human skin organ culture. (A) PRL IR in the control group was significantly greater than that in (B) Substance P treated skin. …”
  4. 884

    Anion-Assisted Glycosylation of Galactose: A Computational Study by Kerli Tali (22769704)

    Published 2025
    “…<i>i</i>PrOH and trichloroacetamide (TCA) present in solution can significantly decrease the energy of the substitution step. This knowledge has then been applied to two saccharide glycosylation reactions described previously by other research groups, where the calculated reaction barriers were found to be too high for the experimental conditions given. …”
  5. 885

    Fig 2 - by David Mathar (9707947)

    Published 2022
    Subjects:
  6. 886
  7. 887
  8. 888
  9. 889
  10. 890

    Distribution Coefficients of the REEs, Sr, Y, Ba, Th, and U between α‑HIBA and AG50W-X8 Resin by Haoyu Li (1672648)

    Published 2020
    “…For all 19 elements, the distribution coefficients decrease with increasing acid concentration. For the REEs, a linear relationship is observed in log–log space between <i>K</i><sub>d</sub> values and α-HIBA molarity. …”
  11. 891

    DataSheet2_Greater than recommended stiffness and power setting of a stance-phase powered leg prosthesis can improve step-to-step transition work and effective foot length ratio du... by Joshua R. Tacca (18067213)

    Published 2024
    “…People with TTA using a stance-phase powered prosthesis (e.g., BiOM, Ottobock, Duderstadt, Germany) walk with increased AL<sub>trail</sub> W<sub>pos</sub> and potentially decreased magnitude of UL<sub>lead</sub> W<sub>neg</sub> compared to a passive-elastic prosthesis. …”
  12. 892
  13. 893
  14. 894
  15. 895
  16. 896
  17. 897
  18. 898

    AZP-531, an unacylated ghrelin analog, improves food-related behavior in patients with Prader-Willi syndrome: A randomized placebo-controlled trial by Soraya Allas (4752756)

    Published 2018
    “…AZP-531, a first-in-class UAG analog, was shown to inhibit the orexigenic effect of AG in animals, to improve glycemic control and decrease body weight in humans. …”
  19. 899
  20. 900